Human Hemangioblast-Derived Mesenchymal Stem Cells Promote Islet Engraftment in a Minimal Islet Mass Transplantation Model in Mice.
hemangioblast-derived mesenchymal cell
human embryonic stem cell
islet transplantation
mesenchymal stem cell
minimal islet mass model
type 1 diabetes
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2021
2021
Historique:
received:
29
01
2021
accepted:
15
03
2021
entrez:
3
5
2021
pubmed:
4
5
2021
medline:
4
5
2021
Statut:
epublish
Résumé
Islet transplantation can restore glycemic control in patients with type 1 diabetes. Using this procedure, the early stages of engraftment are often crucial to long-term islet function, and outcomes are not always successful. Numerous studies have shown that mesenchymal stem cells (MSCs) facilitate islet graft function. However, experimental data can be inconsistent due to variables associated with MSC generation (including donor characteristics and tissue source), thus, demonstrating the need for a well-characterized and uniform cell product before translation to the clinic. Unlike bone marrow- or adipose tissue-derived MSCs, human embryonic stem cell-derived-MSCs (hESC-MSCs) offer an unlimited source of stable and highly-characterized cells that are easily scalable. Here, we studied the effects of human hemangioblast-derived mesenchymal cells (HMCs), (i.e., MSCs differentiated from hESCs using a hemangioblast intermediate), on islet cell transplantation using a minimal islet mass model. The co-transplantation of the HMCs allowed a mass of islets that was insufficient to correct diabetes on its own to restore glycemic control in all recipients. Our
Identifiants
pubmed: 33937296
doi: 10.3389/fmed.2021.660877
pmc: PMC8081894
doi:
Types de publication
Journal Article
Langues
eng
Pagination
660877Informations de copyright
Copyright © 2021 Bertera, Knoll, Knoll, Hara, Kimbrel, Kouris, Lanza, Philips, Garciafigueroa, Giannoukakis, Cooper, Trucco and Bottino.
Déclaration de conflit d'intérêts
EK, NK, and RL are employees of Astellas Institute for Regenerative Medicine, a wholly owned subsidiary of Astellas Pharma engaged in the area of stem cells and regenerative medicine. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Xenotransplantation. 2007 Jul;14(4):288-97
pubmed: 17669170
Cell Commun Signal. 2011 May 14;9:12
pubmed: 21569606
Stem Cell Res Ther. 2019 Mar 12;10(1):85
pubmed: 30867050
Cytotherapy. 2006;8(4):315-7
pubmed: 16923606
Transplantation. 2010 Jun 27;89(12):1438-45
pubmed: 20568673
Stem Cells Transl Med. 2018 Aug;7(8):559-563
pubmed: 29749717
J Clin Endocrinol Metab. 2016 Nov;101(11):4421-4430
pubmed: 27571180
Lancet. 2012 Feb 25;379(9817):713-20
pubmed: 22281388
Nature. 2006 Nov 23;444(7118):481-5
pubmed: 16929302
Diabetes. 2017 May;66(5):1312-1321
pubmed: 28246290
Methods Mol Biol. 2011;690:163-74
pubmed: 21042992
Diabetes. 2002 Aug;51(8):2561-7
pubmed: 12145171
Stem Cells Int. 2012;2012:123030
pubmed: 22645619
PLoS One. 2018 Nov 12;13(11):e0206449
pubmed: 30419033
Cytotherapy. 2013 Aug;15(8):893-904
pubmed: 23751203
Transplantation. 1999 Mar 15;67(5):665-71
pubmed: 10096520
Cell Transplant. 2016;25(5):829-48
pubmed: 26423725
Int J Surg. 2019 Sep;69:100-107
pubmed: 31369877
Cell Transplant. 2012;21(8):1791-802
pubmed: 22776064
Am J Transplant. 2014 Feb;14(2):428-37
pubmed: 24447621
Stem Cell Res Ther. 2017 Sep 29;8(1):199
pubmed: 28962589
Cytotherapy. 2018 Sep;20(9):1124-1142
pubmed: 30068495
Transplantation. 2005 May 27;79(10):1289-93
pubmed: 15912090
Diabetes Care. 2016 Jul;39(7):1230-40
pubmed: 27208344
J Autoimmun. 2009 Mar;32(2):116-24
pubmed: 19217258
Cytotherapy. 2018 Dec;20(12):1427-1436
pubmed: 30377040
Cell Transplant. 2019 Nov;28(11):1455-1460
pubmed: 31359771
Ocul Immunol Inflamm. 2018;26(8):1228-1236
pubmed: 28914568
Nat Protoc. 2007;2(8):1963-72
pubmed: 17703208
Sci Rep. 2015 Dec 02;5:17685
pubmed: 26628350
Stem Cells. 2011 Dec;29(12):2077-89
pubmed: 22052697
Sci Rep. 2015 Mar 30;5:9322
pubmed: 25818803
N Engl J Med. 2000 Jul 27;343(4):230-8
pubmed: 10911004
Diabetes. 1999 Oct;48(10):1907-14
pubmed: 10512353
Sci Rep. 2017 Aug 30;7(1):10059
pubmed: 28855611
Stem Cells Dev. 2014 Jul 15;23(14):1611-24
pubmed: 24650034
Diabetes. 2003 Feb;52(2):387-93
pubmed: 12540612
J Diabetes Res. 2020 Mar 24;2020:5860417
pubmed: 32309447
Xenotransplantation. 2015 Jul-Aug;22(4):317-24
pubmed: 26179209
J Transplant. 2012;2012:856386
pubmed: 23304445
Cell Stem Cell. 2018 Jun 01;22(6):824-833
pubmed: 29859173
Lancet. 2015 Feb 7;385(9967):509-16
pubmed: 25458728
Heliyon. 2018 May 17;4(5):e00632
pubmed: 29872765
Nat Rev Immunol. 2008 Sep;8(9):726-36
pubmed: 19172693
Stem Cell Reports. 2014 Jun 06;3(1):115-30
pubmed: 25068126
PLoS One. 2012;7(10):e47559
pubmed: 23133515
World J Stem Cells. 2014 Apr 26;6(2):163-72
pubmed: 24772243
Diabetologia. 2014 Mar;57(3):522-31
pubmed: 24253203
Diabetes. 2017 Sep;66(9):2531
pubmed: 28663189
Regen Med. 2016 Jan;11(1):33-43
pubmed: 26387424
Islets. 2017 Mar 4;9(2):30-42
pubmed: 28151049